Assessing Neogen (NEOG) Valuation After Earnings Beat But Slower Growth Than Peers

Simply Wall St.05-30

Neogen (NEOG) shares came under pressure after the company reported quarterly earnings and revenue that exceeded analyst estimates, but revenue declined 4.4% year on year and trailed peers on growth. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2639671579?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","is_english":true,"pubTime":"2026-05-30 00:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639671579","market":"hk","top_or_hot":-1,"title":"Assessing Neogen (NEOG) Valuation After Earnings Beat But Slower Growth Than Peers","media":"Simply Wall St.","content":"<div>\n<p>Neogen (NEOG) shares came under pressure after the company reported quarterly earnings and revenue that exceeded analyst estimates, but revenue declined 4.4% year on year and trailed peers on growth. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/assessing-neogen-neog-valuation-after-earnings-beat-but-slow\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Neogen (NEOG) Valuation After Earnings Beat But Slower Growth Than Peers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Neogen (NEOG) Valuation After Earnings Beat But Slower Growth Than Peers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-30 00:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/assessing-neogen-neog-valuation-after-earnings-beat-but-slow><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neogen (NEOG) shares came under pressure after the company reported quarterly earnings and revenue that exceeded analyst estimates, but revenue declined 4.4% year on year and trailed peers on growth. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/assessing-neogen-neog-valuation-after-earnings-beat-but-slow\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEOG","symbol_name":"纽尔真检测","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/assessing-neogen-neog-valuation-after-earnings-beat-but-slow","article_id":"2639671579","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/assessing-neogen-neog-valuation-after-earnings-beat-but-slow","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2639671579","pubTimestamp":1780070889,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Neogen (NEOG) shares came under pressure after the company reported quarterly earnings and revenue that exceeded analyst estimates, but revenue declined 4.4% year on year and trailed peers on growth.\nSee our latest analysis for Neogen.\nAt a share price of $9.30, Neogen has a 1-day share price return of 1.09% and a 7-day share price return of 4.97%. The 90-day share price return is down 17.19%, while the 1-year total shareholder return of 49.76% contrasts with a 3-year total shareholder return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NEOG":"纽尔真检测"},"translate_title":"在盈利超出预期但增长低于同行后评估Neogen(NEOG)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEOG":1.5},"content_text":"Neogen (NEOG) shares came under pressure after the company reported quarterly earnings and revenue that exceeded analyst estimates, but revenue declined 4.4% year on year and trailed peers on growth. See our latest analysis for Neogen. At a share price of $9.30, Neogen has a 1-day share price return of 1.09% and a 7-day share price return of 4.97%. The 90-day share price return is down 17.19%, while the 1-year total shareholder return of 49.76% contrasts with a 3-year total shareholder return that is down 49.81%. This suggests recent momentum has improved after a difficult multi year period. If this earnings reaction has you rethinking where growth could come from next, it may be worth scanning 35 healthcare AI stocks as a starting point for other ideas in related areas. With the stock still trading below the average analyst price target and a long history of mixed returns, the key question now is whether Neogen is undervalued or whether the market is already pricing in future growth. AdvertisementMost Popular Narrative: 22.5% Undervalued With Neogen closing at $9.30 versus a narrative fair value of $12.00, the current price sits well below what this widely followed model implies.  The company's portfolio simplification, divesting lower margin and non core businesses (cleaners and disinfectants, genomics) and focusing on core food safety and animal health verticals, sets the stage for improved net margins and more resilient, higher quality earnings, supported by ongoing deleveraging and reduced operational complexity. Continued investments in R&D and new rapid testing assays (such as the recent launches on the MDS platform), combined with expansion in Europe and other international markets, will allow Neogen to capture share from competitors and participate in the secular growth of high throughput, automated diagnostic solutions, thus boosting both revenue and future earnings potential.  Read the complete narrative. Want to see what kind of revenue trend, margin lift and future earnings multiple are baked into that $12.00 fair value, all discounted at 8.69%? The narrative lays out a detailed path that connects today’s losses, future profitability assumptions and a premium P/E, and it is built on a very specific mix of slower top line expectations and higher margins that might surprise you. Result: Fair Value of $12 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this story can unravel if integration issues around the 3M Food Safety assets persist or if ongoing weakness in Animal Safety continues to weigh on overall revenue. Find out about the key risks to this Neogen narrative. Next Steps Given the mix of optimism and concern in this story, now is a good time to look at the numbers yourself and pressure test the assumptions behind both outcomes. You can start with the 2 key rewards and 1 important warning sign. Looking for more investment ideas? If this earnings story has sharpened your focus, do not stop here. The next step is lining up fresh ideas that match how you like to invest.  Target growth potential without ignoring quality by scanning screener containing 22 high quality undiscovered gems that may have flown under the radar but still show solid fundamentals. Prioritize resilience by checking 64 resilient stocks with low risk scores that score well on stability so short term swings are less likely to knock you off course. Build a core watchlist around strength by reviewing the solid balance sheet and fundamentals stocks screener (46 results) that combine financial discipline with room for future decisions.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Neogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639671579","isCrawlerRequest":true}